--- title: "International Biotechnology (LON:IBT) Stock Price Passes Above 200 Day Moving Average - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/273493698.md" description: "International Biotechnology (LON:IBT) stock has surpassed its 200-day moving average, trading at GBX 982, up 0.4%. The stock's 200-day average is GBX 803.83, with a market cap of £314.64 million and a P/E ratio of -299.77. The company reported an EPS of GBX (11.42) for the last quarter and has a return on equity of 13.67%. Analysts forecast an EPS of 0.94 for the current fiscal year. Despite the stock's performance, it currently holds a Hold rating among analysts, who suggest other stocks may be better investments." datetime: "2026-01-23T09:25:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273493698.md) - [en](https://longbridge.com/en/news/273493698.md) - [zh-HK](https://longbridge.com/zh-HK/news/273493698.md) --- # International Biotechnology (LON:IBT) Stock Price Passes Above 200 Day Moving Average - Here's Why International Biotechnology (LON:IBT - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 803.83 and traded as high as GBX 990. International Biotechnology shares last traded at GBX 982, with a volume of 32,813 shares. ## International Biotechnology Trading Up 0.4% The business has a 50-day moving average price of GBX 955.14 and a two-hundred day moving average price of GBX 803.83. The stock has a market capitalization of £314.64 million, a P/E ratio of -299.77 and a beta of 0.21. International Biotechnology (LON:IBT - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported GBX (11.42) EPS for the quarter. International Biotechnology had a return on equity of 13.67% and a net margin of 90.66%. On average, sell-side analysts forecast that International Biotechnology will post 0.9435943 earnings per share for the current fiscal year. ## About International Biotechnology (Get Free Report) The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. ## Featured Articles - Five stocks we like better than International Biotechnology - Elon Taking SpaceX Public! $100 Pre-IPO Opportunity! - How a Family Trust May Be Able To Help Preserve Your Wealth - Do not delete, read immediately - NEW LAW: Congress Approves Setup For Digital Dollar? - Executive Order 14330: Trump’s Biggest Yet _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in International Biotechnology Right Now? Before you consider International Biotechnology, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list. While International Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IBT.UK](https://longbridge.com/en/quote/IBT.UK.md) ## Related News & Research - [REG - Intnl. Biotechnology - Net Asset Value(s)](https://longbridge.com/en/news/274509800.md) - [REG - Intnl. Biotechnology - Net Asset Value(s)](https://longbridge.com/en/news/273837354.md) - [ZAWYA: Batelco launches Postpaid World for local and international data and calls within the same plan](https://longbridge.com/en/news/286764787.md) - [TBC Bank shareholders back all AGM resolutions amid governance dissent](https://longbridge.com/en/news/286926091.md) - [Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp](https://longbridge.com/en/news/286758697.md)